Hyperoxaluria is a medical condition which
involves increased oxalate in urine. The causes of hyperoxaluria include
consumption of oxalate-rich foods, intestinal disorders and genetic disorders.
The disease is categorized into different types which includes primary
hyperoxaluria, enteric hyperoxaluria and hyperoxaluria related to eating
high-oxalate foods.
Request
to Get the Sample Pages at: https://www.pharmaproff.com/report/hyperoxaluria-therapeutics-pipeline-analysis
The symptoms
observed during hyperoxaluria are severe back pain, blood in urine, frequent
urge to urinate, pain when urinating, and fever. The complications associated
with the hyperoxaluria includes kidney damage, decreased urine output, loss of
appetite, nausea, vomiting, pale skin colour related to anemia and swelling of
hands and feet. Hyperoxaluria is treated by using medications, high fluid
intake, dietary changes, dialysis and transplantation.
Report Description: https://www.pharmaproff.com/request-sample/1124
Allena
Pharmaceuticals Inc. is in the process of developing ALLN-177 as a non-absorbed
oral enzyme that specifically degrades oxalate for the treatment of
hyperoxaluria. Alnylam Pharmaceuticals Inc., and Dicerna Pharmaceuticals Inc.
are some other companies having pipeline drugs for hyperoxaluria.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
